Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bacteroides eggerthii strain:FSDTA-HCK-B-9

ABSTRACT: Bacteroides eggerthii strain:FSDTA-HCK-B-9 Genome sequencing and assembly

PROVIDER: PRJNA609844 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Bacteroides fragilis strain:FSDTA-HCK-B8

Project description:Bacteroides fragilis strain:FSDTA-HCK-B8 Genome sequencing and assembly

| PRJNA609849 | ENA

Bacteroides uniformis strain:FSDTA-HCK-B1

Project description:Bacteroides uniformis strain:FSDTA-HCK-B1 Genome sequencing and assembly

| PRJNA609870 | ENA

Bacteroides ovatus strain:FSDTA-HCK-B4

Project description:Bacteroides ovatus strain:FSDTA-HCK-B4 Genome sequencing and assembly

| PRJNA609877 | ENA

Phocaeicola dorei strain:FSDTA-HCK-B-6

Project description:Phocaeicola dorei strain:FSDTA-HCK-B-6 Genome sequencing and assembly

| PRJNA609839 | ENA

Bacteroides salyersiae strain:FSDTA-ELI-BHI-9

Project description:Bacteroides salyersiae strain:FSDTA-ELI-BHI-9 Genome sequencing and assembly

| PRJNA609882 | ENA

Bacteroides caccae strain:FSDTA-ELH-2.5M-3

Project description:Bacteroides caccae strain:FSDTA-ELH-2.5M-3 Genome sequencing and assembly

| PRJNA609823 | ENA

Bacteroides eggerthii

Project description:Bacteroides eggerthii overview

| PRJNA37309 | ENA

Bacteroides eggerthii strain:FSDTAHCKB9

Project description:Bacteroides eggerthii strain:FSDTAHCKB9 Raw sequence reads

| PRJNA786710 | ENA

Inhibition of the SRC-kinase HCK restricts pancreatic cancer development and metastasis

Project description:Pancreatic cancer is an aggressive disease with a low 5-year survival rate and poor response to therapy. Here, we demonstrate that inhibition of the myeloid-specific SRC family-kinase HCK impairs pancreatic tumor growth and metastasis by enhancing the infiltration of cytotoxic effector cells, stimulating the activation of myeloid cells, and by reducing the desmoplastic microenvironment. Genetic ablation of HCK also maximizes the therapeutic efficacy of chemotherapy and immunotherapy, and improves progression-free survival in mice. Collectively, our results demonstrate that targeting HCK can overcome barriers that limit responses to therapy, and provide a compelling rationale for HCK to be considered as a drug target to improve the responsiveness of pancreatic tumors to chemotherapy and/or immune checkpoint blockade.

2022-10-11 | GSE185540 | GEO

Bacteroides eggerthii CAG:109

Project description:Bacteroides eggerthii CAG:109 overview

| PRJNA207183 | ENA